drugset / Trial / NCT03369223
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
Timeline
- Start
- 2017-12-06
- Primary completion
- 2024-11-07
- Completion
- 2024-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986249 | Unknown | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |